Japan Showcases Central Bank Dangers When Debt Gets Massive
Central banks are generally supposed to focus on keeping prices stable, and for some of them, that's all they're charged with. When they appear to start targeting something else, economists say they're being 'dominated' by that other concern.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Apple's (AAPL) AI Strategy Falls Short, Says Barclays—Is the Stock Still a Must-Watch?
Apple Inc. (NASDAQ:AAPL) is one of the . On July 29, Barclays said it remains cautious on Apple, maintaining its 'Underweight' rating. The analyst highlighted factors such as limited traction on artificial intelligence and risks around tariffs, China, and regulation. The firm said that it anticipates 'a slight June-Q beat led by better FX, iPhone and Mac upside,' helped by tariff-related pull-in. It isn't very optimistic on the stock due to a lack of progress. 'We still see no major progress on AI for AAPL.' Particularly discussing Apple's innovations at the annual developer conference, the firm said that the conference 'underwhelmed with the AI feature announcements, viewing them as more evolutionary than revolutionary.' It further added that 'The reception of Apple Intelligence has also been disappointing.' The firm believes Apple's long-term AI strategy remains muddy and that its light weight approach to AI may or may not be enough to drive an upgrade cycle or growth. Barclays also talked about tariffs, stating that '2H GM remains a wildcard with lack of clarity on tariffs and mitigation efforts.' Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company reported sales of $2.65 billion, up 7% year over year on a reported basis, 8% on constant currency, beating the consensus of $2.32 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Sales of the multiple sclerosis drug Tysabri were down to $454.6 million from $462.2 disease revenue increased 2% year over year (up 3% on constant currency) to $543 million. Spinraza's revenue decreased to $392.7 million from $429.1 million a year ago. Revenues from Skyclarys, acquired via the Reata acquisition, reached $130.3 million during the quarter, up from $100 million a year ago, showing continued growth in demand; U.S. SKYCLARYS revenue of approximately $78 million represents sequential growth of 13%. In Alzheimer's disease, Biogen said Leqembi's U.S. in-market sales of approximately $63 million represent sequential growth of 20%. Global in-market sales of approximately $160 million include a one-time shipment to China of approximately $35 million to optimize global inventory levels. Clinical data presented at AAIC demonstrate that four years of continuous treatment with Leqembi benefits early Alzheimer's patients, including low tau patients, who continue to see sustained improvements in cognitive and daily living function. Outlook Biogen raised its 2025 adjusted earnings guidance from $14.50-$15.50 per share to $15.50-$16.00, compared to the consensus of $14.98. View more earnings on BIIB The updated guidance reflects an 87 cents benefit from an expected stronger business outlook for the full year, partially offset by the ~($0.12) impact from the City Therapeutics transaction. The company expects total revenue for the full year 2025 to be approximately flat, at constant currency, versus the full year 2024, which is up from a mid-single digit decline previously. The outlook reflects the strong first-half revenue performance, including the resilient performance of the U.S. multiple sclerosis business. Biogen expects increased competitive pressures on the ex-U.S. multiple sclerosis business in the second half of 2025, particularly for Tecfidera in Europe. Due to planned plant maintenance activities, Biogen expects minimal contract manufacturing revenue in the fourth quarter of 2025. Potential tariffs, even if the current exemption for pharmaceuticals ends, are not expected to affect the company's 2025 financial outlook. The Fit for Growth program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by the end of 2025. In 2025, Biogen plans to make additional investments in R&D, primarily to support rare diseases. Biogen expects combined Non-GAAP R&D expense and Non-GAAP SG&A expense to total approximately $4 billion in 2025. Price Action: BIIB stock is trading higher by 3.01% to $130.45 at last check Thursday. Read Next:Photo by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? BIOGEN (BIIB): Free Stock Analysis Report This article Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Here's How Much Traders Expect Apple Stock To Move After Earnings Today
Apple (AAPL) is scheduled to report quarterly earnings after the closing bell today, with traders anticipating a sizable move from the iPhone maker's stock. Current options pricing suggests traders are expecting the shares could move 4% in either direction by the end of Friday's trading session from their recent level at $209. A move of that scale could lift the stock above $217, its highest level since shares plunged following President Donald Trump's "Liberation Day " tariffs announcement back in April. At the the low end, that could bring shares down to $200, where they were roughly a month ago. The stock has lost 17% of its value in 2025 so far. Apple stock has registered an average post-earnings move of 2% over the past four quarters, falling in each of those instances. In May, shares fell 4% the day following the company's earnings, after Tim Cook told analysts tariffs could cost Apple $900 million in its fiscal third quarter. Last week, Morgan Stanley analysts cautioned that the Trump administration could soon subject Apple to Section 232 tariffs, which are tied to national security concerns and have held up better in court than country-specific duties. The iPhone maker is widely expected to post rising quarterly sales and profits. Ahead of the results, nine brokers tracked by Visible Alpha have "buy" or equivalent ratings for the stock, compared to one "hold" and one "sell" rating. Their average price target around $235 represents a roughly 12% premium over Wednesday's closing price. Analysts will also be watching for any progress on—or increased investment in—Apple Intelligence, which has been dogged by Siri delays and a lack of availability in China. Read the original article on Investopedia
